Obesity in Young Adulthood Linked to Higher Cancer Risk Into Midlife

Obesity in young adulthood was associated with a higher risk of cancer that persisted into middle age in a nationwide Korean cohort study published in Annals of Internal Medicine. Although the absolute differences were modest, the findings extend evidence on obesity-associated cancers to adults whose long-term cancer risk has received less attention.¹

Among more than 6.3 million adults aged 20 to 39 years at enrollment, the 10-year cumulative incidence of cancer increased from 1.84% in participants with normal weight to 2.62% in those with class 2 obesity. Abdominal obesity added risk beyond BMI alone, suggesting that body fat distribution deserves attention when discussing prevention with younger patients.¹

Following Cancer Risk From Young Adulthood

Investigators analyzed Korean National Health Insurance Service data from 2009 through 2021, identifying 6,313,338 adults without prior cancer who underwent national health examinations between 2009 and 2012. Participants had a mean age of 30.9 years, and 59.3% were men. During a mean follow-up of 11.2 years, 151,893 cancer cases were documented.¹

BMI was categorized into 5 groups using Asian-specific criteria, with class 2 obesity defined as a BMI of at least 30 kg/m². This distinction matters for US readers: a BMI of 30 kg/m² marks the threshold for obesity in standard US adult categories. Investigators also assessed waist circumference and abdominal obesity, adjusting analyses for smoking status, alcohol consumption, physical activity, socioeconomic factors, and comorbid conditions.^1,2

Compared with normal weight, overweight was associated with a higher cancer hazard (HR, 1.10; 95% CI, 1.08–1.11). The association increased for class 1 obesity (HR, 1.22; 95% CI, 1.20–1.24) and class 2 obesity (HR, 1.43; 95% CI, 1.39–1.47).¹

The corresponding 10-year cancer incidences were 1.84% for normal weight, 2.24% for class 1 obesity, and 2.62% for class 2 obesity. The difference between normal weight and class 2 obesity was 0.78 percentage points, equivalent to approximately 8 additional cancer diagnoses per 1000 individuals over 10 years. That absolute difference provides useful context for the 43% higher adjusted hazard.¹

Abdominal Obesity Adds to the Association

Within the class 1 obesity group, participants with abdominal obesity had a 10-year cancer incidence of 2.45%, compared with 2.13% among those without abdominal obesity. Their incidence also exceeded the 2.20% observed in participants with class 2 obesity without abdominal obesity. These findings suggest that BMI alone does not fully capture obesity-associated cancer risk.¹

The relative association was stronger in men. Across overweight, class 1 obesity, and class 2 obesity, HRs were 1.13, 1.29, and 1.58 in men, respectively, compared with 1.08, 1.15, and 1.28 in women. These estimates describe differences relative to normal-weight participants within each sex; they should not be interpreted as a direct comparison of overall cancer incidence between men and women.¹

The publisher’s study summary identified the strongest associations for thyroid, endometrial, and ovarian cancers. The findings fit within broader evidence linking excess body weight to at least 13 cancer types, including colorectal cancer and multiple myeloma. Proposed mechanisms include chronic inflammation and changes in hormonal signaling, although this cohort did not establish the biological pathways responsible for its findings.^1-3

Implications for Pharmacy Practice

For pharmacists, the results provide a basis for discussing weight management as part of long-term preventive care with younger adults. Counseling can place cancer risk alongside the established metabolic consequences of obesity while helping patients access structured lifestyle programs or discuss appropriate obesity treatment with their clinicians.²

The study does not establish that intentional weight loss in early adulthood prevents cancer. Its observational design leaves room for residual confounding, including differences in smoking intensity and duration that smoking-status adjustment does not capture. Findings from a Korean health-screening population also require caution when applied to other populations.¹

Current USPSTF guidance recommends colorectal cancer screening beginning at age 45 years for average-risk, asymptomatic adults. Pharmacists can reinforce guideline-based screening while supporting earlier attention to modifiable risk factors.⁴

REFERENCES

1. Jang Y, Kim T, Choi Y, et al. Association between obesity and cancer risk in adults with HIV in Korea. AIDS. 2024;38(9):1386-1394. doi:10.1097/QAD.0000000000003904

2. Obesity and cancer. CDC. August 28, 2026. Accessed October 28, 2026. https://www.cdc.gov/cancer/risk-factors/obesity.html

3. Obesity and cancer. National Cancer Institute. January 28, 2025. Accessed October 28, 2026. https://www.cancer.gov/about-cancer/causes-prevention/risk/obesity/obesity-fact-sheet

4. US Preventive Services Task Force. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(19):1965–1977. doi:10.1001/jama.2021.6238